DHAI vs MBOT vs BWAY

For growth investors, BrainsWay Ltd.

(BWAY) is the stronger pick with 28. 3% revenue growth year-over-year, versus -2. 5% for DIH Holding US, Inc. (DHAI). BrainsWay Ltd. (BWAY) offers the better valuation at 46. 4x trailing P/E (85. 7x forward), making it the more compelling value choice. Analysts rate Microbot Medical Inc. (MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BrainsWay Ltd.

(BWAY) delivered a total return of +287. 7%, compared to -99. 9% for DIH Holding US, Inc. (DHAI). Over 10 years, the gap is even starker: BWAY returned +201. 1% versus DHAI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DIH Holding US, Inc.

(DHAI) is the lower-risk stock at -1. 13β versus Microbot Medical Inc. 's 1. 85β — meaning MBOT is approximately -265% more volatile than DHAI relative to the S&P 500. On balance sheet safety, Microbot Medical Inc. (MBOT) carries a lower debt/equity ratio of 3% versus 9% for BrainsWay Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BrainsWay Ltd.

(BWAY) is pulling ahead at 28. 3% versus -2. 5% for DIH Holding US, Inc. (DHAI). On earnings-per-share growth, the picture is similar: BrainsWay Ltd. grew EPS 300. 0% year-over-year, compared to 24. 1% for DIH Holding US, Inc.. Over a 3-year CAGR, BWAY leads at 24. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BrainsWay Ltd.

(BWAY) is the more profitable company, earning 14. 6% net margin versus -13. 8% for DIH Holding US, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BWAY leads at 8. 3% versus -7. 7% for DHAI. At the gross margin level — before operating expenses — BWAY leads at 75. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MBOT: 158.

2% to $5. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DIH Holding US, Inc.

(DHAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1. 13)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHAI: -99. 9%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DHAI is a small-cap quality compounder stock; MBOT is a small-cap quality compounder stock; BWAY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.